Navigation Links
InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
Date:2/1/2010

otic and anti-inflammatory effects.  In February 2009, InterMune announced the results of the company's two global Phase 3 clinical trials evaluating pirfenidone for the treatment of IPF, known as the CAPACITY trials.  InterMune believes that these data support the safety and efficacy of pirfenidone in IPF patients on a number of clinical measures.  Prior to initiating the CAPACITY trials, data were previously presented from one Phase 3 study and four Phase 2 clinical trials in more than 400 patients which suggested that pirfenidone may positively affect lung function and disease progression in patients with IPF.  In those clinical studies, pirfenidone was safe and generally well tolerated, with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms.  In October of 2008, pirfenidone was approved for use in IPF patients in Japan and is marketed as Pirespa® by Shionogi & Co. Ltd. in that country.

About IPF

Idiopathic pulmonary fibrosis (IPF) is a disabling and ultimately fatal disease that affects approximately 200,000 people in the United States and Europe combined, with approximately 30,000 new cases reported per year in each of the United States and Europe.

IPF is characterized by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen and causing shortness of breath (dyspnea) and cough and is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity.  The median survival time from diagnosis is two to five years, with a five-year survival rate of approximately 20%.  Patients diagnosed with IPF are usually between the ages of 40 and 70, with a median age of 63 years and
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 2015 Axxess , an industry leader ... software vendor accredited by the American Nursing Credentialing Center ... health agencies select the right revenue cycle management (RCM) ... their business. Research by American Health Information ... expect a decrease in productivity of 54.4 - 69 ...
(Date:6/29/2015)... Md. , June 29, 2015 The ... New Jersey Board of Professional ... a provider of courses to professional engineers for continuing ... accreditation further demonstrates the value and quality of PDA,s ... . "Our lecture courses and hands-on professional training at ...
(Date:6/29/2015)... SOUTH EASTON, Mass. , June 29, 2015 ... the "Company"), a leader in the development and ... sample preparation solutions to the worldwide life sciences ... of the Institute of Molecular Systems Biology, ETH ... the proteomic profiling and classification of prostate cancer ...
Breaking Medicine Technology:Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform 2Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform 3Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform 4
... , CARLSBAD, Calif., Dec. 21 Isis Pharmaceuticals, Inc. (Nasdaq: ... $10 million payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: ... to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is ... has completed a successful Phase 2 program in patients with ...
... , , , STOCKHOLM, December ... raising 380 MSEK (approximately 36,MEUR). This will secure Karolinska Development,s ... "The significant interest in this share issue shows ... us to pursue our long term,investment strategy. I am also ...
Cached Medicine Technology:Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 2Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 3Karolinska Development New Share Issue Completed - Raising 380 MSEK (36 MEUR) 2
(Date:6/30/2015)... ... 2015 , ... Curly Hair Solutions™ is honoured to attend Cosmoprof North America ... featuring products from all over the world. For the first time ever, Curly Hair ... hair styling products focused entirely on meeting the needs of all curl types ...
(Date:6/29/2015)... ... ... Sublime Beauty NATURALS® introduces its new USDA Certified Organic Sesame Oil this ... and even culinary uses, was especially designed for Oil Pulling. , To transform ... can accomplish this. Oil Pulling is an Ayurvedic practice that is easy and very ...
(Date:6/29/2015)... Kentucky (PRWEB) , ... June 30, 2015 , ... The ... Kentucky Orthopedic Rehab Team (KORT) as it becomes the Official Physical and Occupational Therapists ... the 2015 Rolex Kentucky Three-Day Event presented by Land Rover. , “The ...
(Date:6/29/2015)... ... June 30, 2015 , ... The ... Guidelines for Neuro Musculoskeletal Thermography and Sympathetic Skin Response Studies.* , The new ... first published in 2006, are intended to aid physicians and thermal technologists in ...
(Date:6/29/2015)... ... June 29, 2015 , ... Cosmetic Town Journal ... potential patients about a variety of plastic surgery and cosmetic procedures including: breast ... It has been the main focus of Cosmetic Town Journal to become the ...
Breaking Medicine News(10 mins):Health News:Curly Hair Solutions™ Showcases Entire Curl Keeper™ Collection at Cosmoprof Las Vegas July 12 - 14 2Health News:New Product: Transform Wellness and Oral Health With This Ancient Ayurvedic Secret and Organic Product from Sublime Beauty NATURALS® 2Health News:KORT Physical Therapy Announces Partnership with The United States Equestrian Federation 2Health News:American Academy of Thermology Publishes Revised 2015 Guidelines for Neuro-Musculoskeletal Thermography and Sympathetic Skin Response Studies 2Health News:American Academy of Thermology Publishes Revised 2015 Guidelines for Neuro-Musculoskeletal Thermography and Sympathetic Skin Response Studies 3Health News:Board of Advisors Now Coming to Cosmetic Town 2
... Researchers at UT Southwestern Medical Center have found ... circadian rhythm, the 24-hour cycle that controls metabolism, sleep ... the brain called the suprachiasmatic nucleus (SCN) remains the ... it does so indirectly, according to a study published ...
... patient and treatment has become a major focus ... psychopharmacology of mental disorders. Genetic studies have suggested that ... less sensitive to stressful social environments but can ... preventative or therapeutic behavioral interventions? The current ...
... PROVIDENCE, RI New research from the Bradley Hasbro ... a child with obsessive compulsive disorder (OCD) will respond ... The findings, published in the October issue of the ... Adolescent Psychiatry, could help guide important clinical decisions ...
... Dotinga HealthDay Reporter , WEDNESDAY, Oct. 13 (HealthDay ... poor countries could help HIV-infected mothers and their infants more ... doctors lower the risk of transmission of mother-to-baby HIV infection ... to babies right after. About half of the babies avoid ...
... --- Northwestern University Feinberg School of Medicine is among ... initiative to invest $130 million over five years to ... of health workers. Through the Medical Education ... Health at Feinberg will participate in a consortium to ...
... popular lemon-lime soft drink could play an unexpected role ... The experiments produced evidence that patients will absorb more ... clinical trials, when taken with "flat" or degassed Sprite. ... a bi-monthly journal. Faraj Atassi and colleagues note ...
Cached Medicine News:Health News:Temperature rhythms keep body clocks in sync, UT Southwestern researchers find 2Health News:Perspectives on improving patient care: Genetics, personalized medicine, and behavioral intervention 2Health News:New research helps clinicians predict treatment outcomes for children with OCD 2Health News:Studies Tout Alternative HIV Regimens for Women, Babies 2Health News:Studies Tout Alternative HIV Regimens for Women, Babies 3Health News:Improving medical education in Africa 2
For regulating sample flow rate when using the QIAvac 24 Plus;...
For processing mini spin columns on QIAvac 24;...
DNA/RNA preparation in 8-multi channels...
... Filter Units,Filter units with hydrophobic PTFE ... membrane are ideal for the sterilizing ... sterile containers, and for sterilizing or ... mm Millex filter units are available ...
Medicine Products: